Recognizing that new cancer drugs approved for adults are likely to become the off-label standard of care for several pediatric cancers, the FDA's Pediatric Oncology Subcommittee Thursday pondered how to best get the answers needed to advance the science without unduly delaying the approval of new therapies for children.